Clinical Characteristics and Outcomes Among Adults Hospitalized With Laboratory-Confirmed SARS-CoV-2 Infection During Periods of B.1.617.2 (Delta) and B.1.1.529 (Omicron) Variant Predominance

One Hospital, California, July 15-September 23, 2021, and December 21, 2021-January 27, 2022

Matthew E Modes, MD; Michael P. Directo, MD; Michael Melgar, MD; Lily R. Johnson, MPH; Haoshu Yang, PharmD; Priya Chaudhary, MBBS; Susan Bartolini; Norling Kho; Paul W. Noble, MD; Sharon Isonaka, MD; Peter Chen, MD

Disclosures

Morbidity and Mortality Weekly Report. 2022;71(6):217-223.

Abstract and Introduction

Introduction

In mid-December 2021, the B.1.1.529 (Omicron) variant of SARS-CoV-2, the virus that causes COVID-19, surpassed the B.1.617.2 (Delta) variant as the predominant strain in California.^§ Initial reports suggest that the Omicron variant is more transmissible and resistant to vaccine neutralization but causes less severe illness compared with previous variants.^[1–3] To describe characteristics of patients hospitalized with SARS-CoV-2 infection during periods of Delta and Omicron predominance, clinical characteristics and outcomes were retrospectively abstracted from the electronic health records (EHRs) of adults aged ≥18 years with positive reverse transcription–polymerase chain reaction (RT-PCR) SARS-CoV-2 test results admitted to one academic hospital in Los Angeles, California, during July 15–September 23, 2021 (Delta predominant period, 339 patients) and December 21, 2021–January 27, 2022 (Omicron predominant period, 737 patients). Compared with patients during the period of Delta predominance, a higher proportion of adults admitted during Omicron predominance had received the final dose in a primary COVID-19 vaccination series (were fully vaccinated) (39.6% versus 25.1%), and fewer received COVID-19–directed therapies. Although fewer required intensive care unit (ICU) admission and invasive mechanical ventilation (IMV), and fewer died while hospitalized during Omicron predominance, there were no significant differences in ICU admission or IMV when stratified by vaccination status. Fewer fully vaccinated Omicron-period patients died while hospitalized (3.4%), compared with Delta-period patients (10.6%). Among Omicron-period patients, vaccination was associated with lower likelihood of ICU admission, and among adults aged ≥65 years, lower likelihood of death while hospitalized. Likelihood of ICU admission and death were lowest among adults who had received a booster dose. Among the first 131 Omicron-period hospitalizations, 19.8% of patients were clinically assessed as admitted for non–COVID-19 conditions. Compared with adults considered likely to have been admitted because of COVID-19, these patients were younger (median age = 38 versus 67 years) and more likely to have received at least one dose of a COVID-19 vaccine (84.6% versus 61.0%). Although 20% of SARS-CoV-2–associated hospitalizations during the period of Omicron predominance might be driven by non–COVID-19 conditions, large numbers of hospitalizations place a strain on health systems. Vaccination, including a booster dose for those who are fully vaccinated, remains critical to minimizing risk for severe health outcomes among adults with SARS-CoV-2 infection.

Periods of Delta and Omicron predominance (July 15–September 23, 2021, and December 21, 2021–January 27, 2022, respectively) were defined to correspond to peaks in SARS-CoV-2 hospitalizations during which each variant accounted for ≥50% of sequenced SARS-CoV-2 isolates in California (Supplementary Figure, https://stacks. cdc

To continue reading this article ...

Continue reading your article with a Medscape account

Join the Top Medical Resource for Physicians Today. Free Membership!

Abstract and Introduction
Discussion
References
Sidebar

*These authors contributed equally to this report.
^†These senior authors contributed equally to this report.
^§ https://covid19.ca.gov/variants/
^¶This flagging can be triggered in one of two ways: either by a laboratory report indicating a positive SARS–CoV-2 RT-PCR test result from any time during hospitalization or during a 14-day lookback window preceding admission, which included tests performed in ambulatory and inpatient settings, or by admitting physician confirmation of RT-PCR positivity from an outside facility via patient interview, during which time a patient was queried about positive RT-PCR test results and any related COVID-19 symptoms over the preceding 14 days. Hospitalizations were included in the study if they occurred among adults without another hospitalization associated with a positive SARS-CoV-2 RT-PCR result during the preceding 90 days, or if there was a hospitalization associated with a positive RT-PCR result during the preceding 90 days, but the patient's symptoms had resolved before readmission as determined by the admitting provider.
**Fully vaccinated adults were those who were not immunocompromised and had received the second of a 2-dose COVID-19 vaccine series or a single dose of a 1-dose product ≥14 days before receiving a positive SARS-CoV-2 test result associated with their hospitalization. Immunocompromised adults were considered fully vaccinated if they had received a third dose of a 3-dose primary series or a single dose of a 1-dose product ≥14 days before receiving a positive SARS-CoV-2 test result associated with their hospitalization. Fully vaccinated adults were considered to have received a booster dose if they had received an additional dose (third or fourth) of an mRNA COVID-19 vaccine ≥14 days before receiving a positive SARS-CoV-2 test result associated with their hospitalization. Adults whose positive SARS-CoV-2 test date was ≥14 days after the first dose of a 2-dose series (or second dose of a 3-dose series) but <14 days after receipt of the second dose (or third dose) were considered partially vaccinated, as were those who had received only a single dose of a 2-dose series (or 1 or 2 doses of a 3-dose series). Adults with no documented receipt of any COVID-19 vaccine dose before the test date were considered unvaccinated.
^††Chart review included notes by the emergency department provider, admitting provider, initial infectious disease consultant (when consulted), and discharging provider when available. Admissions associated with a positive SARS-CoV-2 RT-PCR result were classified as likely due to COVID-19 if the admitting provider affirmed that COVID-19 was the reason for admission or, in the absence of explicit determination, if reviewers could not determine a clear alternative reason for admission that was not plausibly linked to SARS-CoV-2 infection. Alternative reasons for admission included uncomplicated labor, a surgical procedure, trauma, psychiatric care, or a medical diagnosis not plausibly linked to COVID-19 (cellulitis [six patients], gastrointestinal bleeding [two], small bowel obstruction [two], and osteomyelitis [one]). Exacerbations of chronic conditions (e.g., congestive heart failure, chronic obstructive pulmonary disease, and asthma) were attributed to COVID-19. Any positive RT-PCR test results ≥7 days after initial negative test results on admission were considered to represent nosocomial SARS-CoV-2 infections, and therefore, the admission was not attributed to COVID-19. This applied to three hospitalizations included in this report.
^§§ https://www.cdc.gov/media/releases/2021/p0924-booster-recommendations-.html
^¶¶45 C.F.R. part 46; 21 C.F.R. part 56.

Table 1. Demographic characteristics, clinical characteristics, and clinical outcomes among 1,076 hospitalized adults with SARS-CoV-2 infection by vaccination status and period of variant predominance — one hospital, California, July 15–September 23, 2021 (Delta period) and December 21, 2021–January 27, 2022 (Omicron period)
Characteristic	No. (%)
	Total hospitalizations (N = 1,076)			Unvaccinated (n = 657)			Fully vaccinated (n = 377)
	Delta period	Omicron period	p-value	Delta period	Omicron period	p-value	Delta period	Omicron period	p-value
Total	339	737	—	241	416	—	85	292	—
*Vaccination status^,†**
Unvaccinated	241 (71.1)	416 (56.4)	<0.01	241 (100)	416 (100)	—	—	—	—
At least 1 dose	98 (28.9)	321 (43.6)	<0.01	—	—	—	85 (100)	292 (100)	—
Fully vaccinated	85 (25.1)	292 (39.6)	<0.01	—	—	—	85 (100)	292 (100)	—
Fully vaccinated and booster dose	—^§	70 (9.5)	—	—	—	—	—^§	70 (24.0)	—
Age, yrs, median (IQR)	60 (43–73)	66 (49–79)	<0.01	54 (38–68)	64 (48–78)	<0.01	71 (5–82)	69 (51–80)	0.36
Sex
Men	190 (56.0)	377 (51.2)	0.15	130 (53.9)	221 (53.1)	0.87	52 (61.2)	142 (48.6)	0.05
Women	149 (44.0)	360 (48.8)	0.15	111 (46.1)	195 (46.9)	0.87	33 (38.8)	150 (51.4)	0.05
Race and ethnicity
White, non-Hispanic	163 (48.1)	336 (45.6)	0.47	105 (43.6)	184 (44.2)	0.94	53 (62.4)	136 (46.6)	0.01
Black, non-Hispanic	69 (20.4)	145 (19.7)	0.81	54 (22.4)	87 (20.9)	0.69	12 (14.1)	52 (17.8)	0.51
Hispanic	56 (16.5)	157 (21.3)	0.07	45 (18.7)	87 (20.9)	0.54	9 (10.6)	64 (21.9)	0.02
Asian, non-Hispanic	10 (2.9)	33 (4.5)	0.31	4 (1.7)	17 (4.1)	0.11	6 (7.1)	16 (5.5)	0.60
Other, non-Hispanic^¶	41 (12.1)	66 (9.0)	0.12	33 (13.7)	41 (9.9)	0.16	5 (5.9)	24 (8.2)	0.64
COVID-19 therapies received
Any	273 (80.5)	412 (55.9)	<0.01	197 (81.7)	241 (57.9)	<0.01	65 (76.5)	153 (52.4)	<0.01
Dexamethasone	245 (72.3)	360 (48.8)	<0.01	178 (73.9)	216 (51.9)	<0.01	57 (67.1)	129 (44.2)	<0.01
Remdesivir	234 (69.0)	293 (39.8)	<0.01	170 (70.5)	173 (41.6)	<0.01	54 (63.5)	106 (36.3)	<0.01
Other therapies**	76 (22.4)	92 (12.5)	<0.01	47 (19.5)	58 (13.9)	0.08	23 (27.1)	30 (10.3)	<0.01
Intensive care unit admission	79 (23.3)	124 (16.8)	0.01	55 (22.8)	79 (19.0)	0.27	20 (23.5)	34 (15.3)^††	0.10
Invasive mechanical ventilation	46 (13.6)	68 (9.2)	0.03	37 (15.4)	45 (10.8)	0.11	8 (9.4)	19 (8.6)^††	0.82
Death while hospitalized	28 (8.3)	22 (4.0)^§§	0.01	19 (7.9)	14 (4.9)^¶¶	0.21	9 (10.6)	6 (3.4)***	0.02

*Vaccination status was ascertained from the California Immunization Registry. Fully vaccinated adults were those who were not immunocompromised and had received the second dose of a 2-dose COVID-19 vaccine series or a single dose of a 1-dose product ≥14 days before receiving a positive SARS-CoV-2 test result associated with their hospitalization. Immunocompromised adults were considered fully vaccinated if they had received a third dose of a 3-dose primary series or a single dose of a 1-dose product ≥14 days before receiving a positive SARS-CoV-2 test result associated with their hospitalization. Fully vaccinated adults were considered to have received a booster dose if they had received an additional dose (third or fourth) of an mRNA COVID-19 vaccine ≥14 days before receiving a positive SARS-CoV-2 test result associated with their hospitalization. Adults whose positive SARS-CoV-2 test date was ≥14 days after the first dose of a 2-dose series (or second dose of a 3-dose series) but <14 days after receipt of the second dose (or third dose) were considered partially vaccinated, as were those who had received only a single dose of a 2-dose product (or 1 or 2 doses of a 3-dose series). Adults with no documented receipt of any COVID-19 vaccine dose before the test date were considered unvaccinated.
^†Partially vaccinated adults were not included in analyses stratified by vaccination status because of small sample size. However, they were included in overall proportions and comparisons not stratified by vaccination status; thus, the total number of patients exceeds the sum of fully vaccinated and unvaccinated patients.
^§Vaccination status was ascertained from the California Immunization Registry. Booster status was unavailable for hospitalizations before December 1, 2021.
^¶Includes Native Hawaiian, other Pacific Islander, American Indian, and Alaska Native persons, and persons of unknown race or ethnicity.
**Includes baricitinib, casirivimab-imdevimab, convalescent plasma, sotrovimab, and tocilizumab.
^††Denominator excludes 70 fully vaccinated patients who also received a booster dose.
^§§Denominator excludes 188 patients who remained hospitalized as of January 27, 2022.
^¶¶Denominator excludes 129 patients who remained hospitalized as of January 27, 2022
***Denominator excludes 70 fully vaccinated patients who also received a booster dose and 43 patients who remained hospitalized as of January 27, 2022.

Table 2. Demographic and clinical characteristics and clinical outcomes among 131 adults hospitalized with SARS-CoV-2 infection during early Omicron variant predominance, by primary reason for admission — one hospital, California, December 21, 2021–January 2, 2022
Characteristic	No. (column %)			p-value
Characteristic	Total hospitalizations (N = 131)	Hospitalizations not likely due to COVID-19 (n = 26)	Hospitalizations likely due to COVID-19 (n = 105)	p-value
Age, yrs, median (IQR)	63 (38–79)	38 (29–62)	67 (47–79)	<0.01
Sex
Men	61 (46.6)	11 (42.3)	50 (47.6)
Women	70 (53.4)	15 (57.7)	55 (52.4)	0.67
Race and ethnicity
White, non-Hispanic	59 (45.0)	9 (34.6)	50 (47.6)	0.28
Hispanic	32 (24.4)	10 (38.5)	22 (21.0)	0.08
Black, non-Hispanic	26 (19.8)	5 (19.2)	21 (20.0)	>0.99
Asian, non-Hispanic	5 (3.8)	2 (7.7)	3 (2.9)	0.26
Other, non-Hispanic*	9 (6.9)	0 (—)	9 (8.6)	0.20
Vaccination status^†
Unvaccinated	45 (34.4)	4 (15.4)	41 (39.0)	0.02
At least 1 dose	86 (65.6)	22 (84.6)	64 (61.0)	0.02
Fully vaccinated	80 (61.1)	20 (76.9)	60 (57.1)	0.07
Fully vaccinated and booster dose	18 (13.7)	4 (15.4)	14 (13.3)	0.76
Initial symptoms and signs
Lower respiratory symptoms^§	68 (51.9)	1 (3.8)	67 (63.8)	<0.01
Abnormal chest radiograph^¶	55 (42.0)	1 (3.8)	54 (51.4)	<0.01
Hypoxemia	41 (31.3)	0 (—)	41 (39.0)	<0.01
Fever**	39 (29.8)	5 (19.2)	34 (32.4)	0.24
Gastrointestinal symptoms^††	32 (24.4)	7 (26.9)	25 (23.8)	0.80
Underlying medical conditions
Obesity (BMI ≥30)	46 (35.1)	8 (30.8)	38 (36.2)	0.65
Renal disease	14 (10.7)	2 (7.7)	12 (11.4)	0.74
Hypertension	13 (9.9)	0 (—)	13 (12.4)	0.07
Cardiovascular disease^§§	11 (8.4)	0 (—)	11 (10.5)	0.11
Diabetes mellitus	6 (4.6)	0 (—)	6 (5.7)	0.60
Chronic pulmonary disease^¶¶	2 (1.5)	0 (—)	2 (1.9)	>0.99
COVID-19 therapies administered
Any	73 (55.7)	4 (15.4)	69 (65.7)	<0.01
Dexamethasone	63 (48.1)	3 (11.5)***	60 (57.1)	<0.01
Remdesivir	51 (38.9)	2 (7.7)^†††	49 (46.7)	<0.01
Other therapies^§§§	29 (19.8)	0 (—)	26 (24.8)	<0.01
Intensive care unit admission	17 (13.0)	2 (7.7)	15 (14.3)	0.52
Invasive mechanical ventilation	12 (9.2)	2 (7.7)	10 (9.5)	>0.99
Death while hospitalized	2 (1.9)^¶¶¶	0 (—)****	2 (2.4)^††††	>0.99

Abbreviation: BMI = body mass index.
*Includes Native Hawaiian, other Pacific Islander, American Indian, and Alaska Native persons, and persons of unknown race or ethnicity.
^†Fully vaccinated adults were those who were not immunocompromised and had received the second dose of a 2-dose COVID-19 vaccine series or a single dose of a 1-dose product ≥14 days before receiving a positive SARS-CoV-2 test result associated with their hospitalization. Immunocompromised adults were considered fully vaccinated if they had received a third dose of a 3-dose primary series or a single dose of a 1-dose product ≥14 days before receiving a positive SARS-CoV-2 test result associated with their hospitalization. Fully vaccinated adults were considered to have received a booster dose if they had received an additional (third or fourth) dose of an mRNA COVID-19 vaccine ≥14 days before receiving a positive SARS-CoV-2 test result associated with their hospitalization. Adults whose positive SARS-CoV-2 test date was ≥14 days after the first dose of a 2-dose series (or second dose of a 3-dose series) but <14 days after receipt of the second dose (or third dose) were considered partially vaccinated, as were those who had received only a single dose of a 2-dose product (or 1 or 2 doses of a 3-dose series). Adults with no documented receipt of any COVID-19 vaccine dose before the test date were considered unvaccinated.
^§Includes dyspnea, cough, and wheezing.
^¶Includes presence of opacities or nonspecific densities.
**Either documented temperature >100.4°F (38°C) on admission or identification of fever in a clinical note by the emergency physician or admitting provider.
^††Includes nausea, vomiting, and diarrhea.
^§§Includes coronary artery disease, congestive heart failure, arrhythmias, valvular heart disease, stroke, and peripheral vascular disease.
^¶¶Includes chronic obstructive pulmonary disease, pulmonary fibrosis, and asthma.
***Dexamethasone was administered for neurosurgical indications (two) and for suspected bacterial meningitis (one).
^†††Remdesivir was administered in the setting of difficulty extubating after a gastrointestinal procedure (one) and for unclear indication in a patient admitted for psychiatric care (one).
^§§§Includes baricitinib, casirivimab-imdevimab, convalescent plasma, sotrovimab, and tocilizumab.
^¶¶¶Denominator does not include 25 patients who remained hospitalized as of January 11, 2022.
****Denominator does not include two patients who remained hospitalized as of January 11, 2022.
^††††Denominator does not include 23 patients who remained hospitalized as of January 11, 2022.

processing....

Clinical Characteristics and Outcomes Among Adults Hospitalized With Laboratory-Confirmed SARS-CoV-2 Infection During Periods of B.1.617.2 (Delta) and B.1.1.529 (Omicron) Variant Predominance

One Hospital, California, July 15-September 23, 2021, and December 21, 2021-January 27, 2022

Abstract and Introduction

Introduction

Tables

Tables

References

Authors and Disclosures

Authors and Disclosures

Sidebar

Sidebar

Summary

Figure.

Figure.

Most Popular Articles

Email This

Feedback